Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Indivior shares dive after Dr Reddy's gets FDA approval for generic

Published 15/06/2018, 11:28
Updated 15/06/2018, 11:30
© Reuters.  Indivior shares dive after Dr Reddy's gets FDA approval for generic

© Reuters. Indivior shares dive after Dr Reddy's gets FDA approval for generic

(Reuters) - Britain's Indivior (L:INDV) fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue.

Shares in Indivior, which was spun out from Reckitt Benckiser (L:RB) in 2014, were down 22.7 percent at 0925 GMT and the biggest loser on the FTSE midcap index (FTMC).

India's Dr Reddy's Laboratories (NS:REDY) received FDA approval for a copy-cat version of the treatment, which has been rapidly losing market share due to competition from generics.

Mylan NV (O:MYL) also received approval to market the substitute drug.

Dr Reddy's said it would launch its therapeutic equivalent of Suboxone, which is a composition of buprenorphine and naloxone, at risk, with an approved risk evaluation and mitigation strategy (REMS) programme.

One analyst said the at-risk sudden launch was a surprise and could threaten Indivior's 2018 guidance.

A spokesman for Indivior said the company was preparing to release a statement.

Indivior could seek an injunction to try to halt a launch of the generics or launch its own authorised generic, analysts at Jefferies said in a note.

"If Indivior was to prevail in any of its on-going legal challenges then Dr. Reddy's would be liable for damages," Jefferies said, estimating that Indivior's 2018 earnings per share could be hit by as much as 50 percent if Dr. Reddy's has sufficient inventory and launches by July 1.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.